{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:42:11Z","timestamp":1778816531875,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.jacl.2015.05.001","type":"journal-article","created":{"date-parts":[[2015,5,14]],"date-time":"2015-05-14T01:57:29Z","timestamp":1431568649000},"page":"607-617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide"],"prefix":"10.1016","volume":"9","author":[{"given":"Jeanine","family":"Roeters van Lennep","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Averna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2015.05.001_bib1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(11)61476-1","article-title":"Homozygous familial hypercholesterolaemia","volume":"379","author":"Macchiaiolo","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.05.001_bib2","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1172\/JCI200318925","article-title":"Monogenic hypercholesterolemia: new insights in pathogenesis and treatment","volume":"111","author":"Rader","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2015.05.001_bib3","first-page":"49","article-title":"Familial hypercholesterolaemia","volume":"25","author":"Marais","year":"2004","journal-title":"Clin Biochem Rev"},{"key":"10.1016\/j.jacl.2015.05.001_bib4","series-title":"The metabolic basis of inherited disease","first-page":"2863","article-title":"Familial hypercholesterolemia","author":"Goldstein","year":"2001"},{"key":"10.1016\/j.jacl.2015.05.001_bib5","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2012.02.019","article-title":"Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment","volume":"223","author":"Raal","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.05.001_bib6","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2015.05.001_bib7","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.05.001_bib8","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","article-title":"Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia","volume":"105","author":"Gagn\u00e9","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.05.001_bib9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1055\/s-2004-822985","article-title":"Homozygous familial hypercholesterolemia and its management","volume":"4","author":"Marais","year":"2004","journal-title":"Semin Vasc Med"},{"key":"10.1016\/j.jacl.2015.05.001_bib10","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.amjcard.2008.06.049","article-title":"Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia","volume":"102","author":"Hudgins","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2015.05.001_bib11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.atherosclerosis.2009.06.010","article-title":"Efficacy criteria and cholesterol targets for LDL apheresis","volume":"208","author":"Thompson","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.05.001_bib12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0021-9150(00)00371-3","article-title":"The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels","volume":"152","author":"Kroon","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.05.001_bib13","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/MOL.0b013e3283402f53","article-title":"Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe","volume":"21","author":"Thompson","year":"2010","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2015.05.001_bib14","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.05.001_bib15","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.05.001_bib16","unstructured":"Aegerion Pharmaceuticals Inc. Juxtapid prescribing information.\u00a02013."},{"key":"10.1016\/j.jacl.2015.05.001_bib17","unstructured":"Aegerion Pharmaceuticals Inc. Lojuxta summary of product characteristics.\u00a02013."},{"key":"10.1016\/j.jacl.2015.05.001_bib18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0005-2760(96)00168-3","article-title":"Microsomal triglyceride transfer protein","volume":"1345","author":"Wetterau","year":"1997","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jacl.2015.05.001_bib19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.05.001_bib20","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/MOL.0b013e32836139df","article-title":"Microsomal transfer protein in humans","volume":"24","author":"Cuchel","year":"2013","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2015.05.001_bib21","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.2337\/dc06-2247","article-title":"Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients","volume":"30","author":"Targher","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2015.05.001_bib22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1467-789X.2004.00126.x","article-title":"Hepatic steatosis in obese patients: clinical aspects and prognostic significance","volume":"5","author":"Festi","year":"2004","journal-title":"Obes Rev"},{"key":"10.1016\/j.jacl.2015.05.001_bib23","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3109\/07853890.2010.518623","article-title":"Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity","volume":"43","author":"Musso","year":"2011","journal-title":"Ann Med"},{"key":"10.1016\/j.jacl.2015.05.001_bib24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3909\/ricm0735","article-title":"Lomitapide for the management of homozygous familial hypercholesterolemia","volume":"15","author":"deGoma","year":"2014","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.jacl.2015.05.001_bib25","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome","volume":"36","author":"Sjouke","year":"2015","journal-title":"Eur Heart J"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287415002366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287415002366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,8]],"date-time":"2022-05-08T02:41:52Z","timestamp":1651977712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287415002366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S1933287415002366"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2015.05.001","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2015.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 National Lipid Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}